Abstract
Bone marrow biopsies of 850 patients with chronic myeloproliferative disorders were taken at initial diagnosis; and 169 sequential biopsies over periods of one to 188 months. Three micron sections of all biopsies were evaluated semiquantitatively with reference to the proliferating cell lines, anomalies of megakaryocytes, and fibrosis or osteosclerosis. Correlations between initial histological findings, clinical, haematological, and survival data were analysed statistically. The predominant cell lines distinguished the classical entities of polycythaemia vera, primary thrombocythaemia, and chronic myeloid leukaemia and correlated with their different prognoses, while megakaryocytes characterised subgroups that were prone to fibrotic or blastic transformation. Based on the initial histological, clinical, and haematological data analysed a working classification of chronic myeloproliferative disorders was proposed that permits recognition of both typical and atypical cases of chronic myeloproliferative disorders.
Full text
PDF![237](https://cdn.ncbi.nlm.nih.gov/pmc/blobs/edf0/499756/ecab8e07f52a/jclinpath00198-0001.png)
![238](https://cdn.ncbi.nlm.nih.gov/pmc/blobs/edf0/499756/730af634a21d/jclinpath00198-0002.png)
![239](https://cdn.ncbi.nlm.nih.gov/pmc/blobs/edf0/499756/101cdd6e8b6b/jclinpath00198-0003.png)
![240](https://cdn.ncbi.nlm.nih.gov/pmc/blobs/edf0/499756/f8fb6cff0c9f/jclinpath00198-0004.png)
![241](https://cdn.ncbi.nlm.nih.gov/pmc/blobs/edf0/499756/452727d53dbb/jclinpath00198-0005.png)
![242](https://cdn.ncbi.nlm.nih.gov/pmc/blobs/edf0/499756/db2204ad6e41/jclinpath00198-0006.png)
![243](https://cdn.ncbi.nlm.nih.gov/pmc/blobs/edf0/499756/bc1e2d050ce4/jclinpath00198-0007.png)
![244](https://cdn.ncbi.nlm.nih.gov/pmc/blobs/edf0/499756/3e389b540a93/jclinpath00198-0008.png)
![245](https://cdn.ncbi.nlm.nih.gov/pmc/blobs/edf0/499756/031fb5f4a9ba/jclinpath00198-0009.png)
![246](https://cdn.ncbi.nlm.nih.gov/pmc/blobs/edf0/499756/12e8bba07e71/jclinpath00198-0010.png)
![247](https://cdn.ncbi.nlm.nih.gov/pmc/blobs/edf0/499756/e9fc1a046011/jclinpath00198-0011.png)
![248](https://cdn.ncbi.nlm.nih.gov/pmc/blobs/edf0/499756/81c2272b2b0a/jclinpath00198-0012.png)
![249](https://cdn.ncbi.nlm.nih.gov/pmc/blobs/edf0/499756/2419e9db308d/jclinpath00198-0013.png)
![250](https://cdn.ncbi.nlm.nih.gov/pmc/blobs/edf0/499756/7b165cafe4a6/jclinpath00198-0014.png)
![251](https://cdn.ncbi.nlm.nih.gov/pmc/blobs/edf0/499756/aaf11527111a/jclinpath00198-0015.png)
![252](https://cdn.ncbi.nlm.nih.gov/pmc/blobs/edf0/499756/38a0e44af534/jclinpath00198-0016.png)
Images in this article
Selected References
These references are in PubMed. This may not be the complete list of references from this article.
- Burkhardt R., Bartl R., Jäger K., Frisch B., Kettner G., Mahl G., Sund M. Chronic myeloproliferative disorders (CMPD). Pathol Res Pract. 1984 Nov;179(2):131–186. doi: 10.1016/S0344-0338(84)80124-7. [DOI] [PubMed] [Google Scholar]
- Castro-Malaspina H., Moore M. A. Pathophysiological mechanisms operating in the development of myelofibrosis: role of megakaryocytes. Nouv Rev Fr Hematol. 1982;24(4):221–226. [PubMed] [Google Scholar]
- DAMESHEK W. Some speculations on the myeloproliferative syndromes. Blood. 1951 Apr;6(4):372–375. [PubMed] [Google Scholar]
- Georgii A., Vykoupil K. F., Thiele J. Chronic megakaryocytic granulocytic myelosis-CMGM. A subtype of chronic myeloid leukemia. Virchows Arch A Pathol Anat Histol. 1980;389(3):253–268. doi: 10.1007/BF00430654. [DOI] [PubMed] [Google Scholar]
- Thiele J., Funke S., Holgado S., Choritz H., Georgii A. Megakaryopoiesis in chronic myeloproliferative diseases. A morphometric evaluation with special emphasis on primary thrombocythemia. Anal Quant Cytol. 1984 Sep;6(3):155–167. [PubMed] [Google Scholar]